Medtronic plc (MDT)
| Previous close | 80.23 |
| Open | 80.34 |
| Bid | 79.18 x 800 |
| Ask | 79.16 x 800 |
| Day's range | 78.79 - 80.49 |
| 52-week range | 68.84 - 92.02 |
| Volume | |
| Avg. volume | 6,376,996 |
| Market cap | 105.163B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 25.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.76 (3.44%) |
| Ex-dividend date | 21 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.
- PR Newswire
The Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib). Interim findings from the first-in-human Sphere-360 study were presented as a late-breaking clinical trial at the European Heart Rhythm Association (EHRA) 2024 Annual Meeting.
- PR Newswire
SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), were presented as a late breaking clinical trial at the American College of Cardiology Annual Scientific Session and simultaneously published in The New England Journal of Medicine. The one-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial in individuals with aortic
